卵巢上皮肿瘤血管内皮生长因子受体3和CD31表达与肿瘤转移的研究

目的:研究卵巢肿瘤组织血管内皮生长因子受体3(VEGFR-3)和CD 31的表达与新生淋巴管和血管的生成及肿瘤转移的关系。方法: 采用免疫组织化学及图像分析方法,检测29例卵巢上皮癌和19例良性肿瘤组织中VEGFR-3 和CD31的表达,计数VEGFR-3阳性淋巴管数 (MLC) 和微脉管密度(MVD)。结果: 卵巢上皮癌MLC和MVD显著高于良性肿瘤和正常组织(MLC, P＜0.05; MVD, P＜0.01)。有淋巴转移的卵巢上皮癌患者MLC和MVD显著高于无淋巴转移患者(P＜0.05)。卵巢上皮癌临床分期Ⅲ-Ⅳ期患者的MLC和MVD显著高于Ⅰ-Ⅱ期(MLC,P＜0.05;MVD,P＜0.01)。卵巢上皮癌MLC和MVD在不同的组织学类型和组织学分级无显著差异(P＞0.05)。结论: 卵巢上皮肿瘤组织VEGFR-3和CD31的表达水平与肿瘤的转移密切相关;MLC和MVD提示肿瘤组织有淋巴管和血管的生成,可作为判断肿瘤转移的生物学指标。

Expression of VEGFR- 3, CD31 and their correlation with metastasis in ovarian epithelial tumors

AIM: To investigate the expression of vascular endothelial growth factor receptor-3 (VEGFR-3) and CD31 in relation to metastasis in ovarian epithelial tumors. METHODS: VEGFR-3 and CD31 expression were examined by immunohistochemical methods, VEGFR-3 positive microlymphatic count (MLC) and microvessel density (MVD) were assessed by the image analysis. RESULTS: Both MLC and MVD in ovarian epithelial carcinomas were higher than those in benign tumors(MLC, P＜0.05; MVD, P＜0.01). In ovarian epithelial carcinomas, MLC and MVD were higher in the cases of clinical stage Ⅲ-Ⅳ and with lymphatic metastasis than those of clinical stage Ⅰ-Ⅱ and without lymphatic metastasis, respectively (P＜0.05 or P＜0.01) . There were no significant differences between MLC, MVD and histologic type, histologic grade(differentiation) in ovarian epithelial carcinomas(P＞0.05). CONCLUSIONS: VEGFR-3 and CD31 expression correlate significantly with metastasis, MLC and MVD might predict peritumoral lymphangiogenesis and angiogenesis, which may be as a biologic marker for metastasis in ovarian epithelial tumors.